11 results on '"Ho SB"'
Search Results
2. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis
- Author
-
Bresalier, RS, primary, Ho, SB, additional, Schoeppner, HL, additional, Kim, YS, additional, Sleisenger, MH, additional, Brodt, P, additional, and Byrd, JC, additional
- Published
- 1996
- Full Text
- View/download PDF
3. Reply.
- Author
-
Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, and Ioannou GN
- Subjects
- Humans, Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms
- Published
- 2019
- Full Text
- View/download PDF
4. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis.
- Author
-
Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, and Ioannou GN
- Subjects
- Carcinoma, Hepatocellular blood, Carcinoma, Hepatocellular therapy, Case-Control Studies, Cause of Death, Humans, Liver Cirrhosis therapy, Liver Neoplasms blood, Liver Neoplasms therapy, Male, Middle Aged, Predictive Value of Tests, Prognosis, Risk Factors, Time Factors, United States epidemiology, United States Department of Veterans Affairs, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular mortality, Early Detection of Cancer methods, Liver Cirrhosis diagnosis, Liver Cirrhosis mortality, Liver Neoplasms diagnosis, Liver Neoplasms mortality, Ultrasonography, alpha-Fetoproteins analysis
- Abstract
Background & Aims: Screening patients with cirrhosis for hepatocellular carcinoma (HCC) has been recommended. We conducted a matched case-control study within the US Veterans Affairs (VA) health care system to determine whether screening by abdominal ultrasonography (USS) and/or by measuring serum level of α-fetoprotein (AFP) was associated with decreased cancer-related mortality in patients with cirrhosis., Methods: We defined cases (n = 238) as patients with cirrhosis who died of HCC from January 1, 2013 through August 31, 2015 and had been in VA care with a diagnosis of cirrhosis for at least 4 years before the diagnosis of HCC. We matched each case to 1 control (n = 238), defined as a patient with cirrhosis who did not die of HCC and had been in VA care for at least 4 years before the date of the matched case's HCC diagnosis. Controls were matched to cases by year of cirrhosis diagnosis, race and ethnicity, age, sex, etiology of cirrhosis, Model for End-Stage Liver Disease score, and VA medical center. We identified all USS and serum AFP tests performed within 4 years before the date of HCC diagnosis in cases or the equivalent index date in controls and determined by chart extraction (blinded to case or control status) whether these tests were performed for screening., Results: There were no significant differences between cases and controls in the proportions of patients who underwent screening USS (52.9% vs 54.2%), screening measurement of serum AFP (74.8% vs 73.5%), screening USS or measurement of serum AFP (81.1% vs 79.4%), or screening USS and measurement of serum AFP (46.6% vs 48.3%) within 4 years before the index date, with or without adjusting for potential confounders. There also was no difference in receipt of these screening tests within 1, 2, or 3 years before the index date., Conclusions: In a matched case-control study of the VA health care system, we found that screening patients with cirrhosis for HCC by USS, measurement of serum AFP, either test, or both tests was not associated with decreased HCC-related mortality. We encourage additional case-control studies to evaluate the efficacy of screening for HCC in other health care systems, in which available records are sufficiently detailed to enable identification of the indication for USS and AFP tests., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
5. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice.
- Author
-
Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, and Schnabl B
- Subjects
- Animals, Bacteria classification, Bacteria isolation & purification, Bacterial Translocation, Disease Models, Animal, Dysbiosis, Fatty Acids biosynthesis, Feces chemistry, Feces microbiology, Host-Pathogen Interactions, Intestinal Mucosa metabolism, Lactobacillus metabolism, Liver Diseases, Alcoholic etiology, Liver Diseases, Alcoholic metabolism, Liver Diseases, Alcoholic microbiology, Male, Metabolomics, Metagenome, Mice, Inbred C57BL, Permeability, Time Factors, Bacteria metabolism, Dietary Supplements, Ethanol, Fatty Acids administration & dosage, Intestines microbiology, Liver Diseases, Alcoholic prevention & control
- Abstract
Background & Aims: Alcoholic liver disease is a leading cause of mortality. Chronic alcohol consumption is accompanied by intestinal dysbiosis, and development of alcoholic liver disease requires gut-derived bacterial products. However, little is known about how alterations to the microbiome contribute to pathogenesis of alcoholic liver disease., Methods: We used the Tsukamoto-French mouse model, which involves continuous intragastric feeding of isocaloric diet or alcohol for 3 weeks. Bacterial DNA from the cecum was extracted for deep metagenomic sequencing. Targeted metabolomics assessed concentrations of saturated fatty acids in cecal contents. To maintain intestinal metabolic homeostasis, diets of ethanol-fed and control mice were supplemented with saturated long-chain fatty acids (LCFA). Bacterial genes involved in fatty acid biosynthesis, amounts of lactobacilli, and saturated LCFA were measured in fecal samples of nonalcoholic individuals and patients with active alcohol abuse., Results: Analyses of intestinal contents from mice revealed alcohol-associated changes to the intestinal metagenome and metabolome, characterized by reduced synthesis of saturated LCFA. Maintaining intestinal levels of saturated fatty acids in mice resulted in eubiosis, stabilized the intestinal gut barrier, and reduced ethanol-induced liver injury. Saturated LCFA are metabolized by commensal Lactobacillus and promote their growth. Proportions of bacterial genes involved in fatty acid biosynthesis were lower in feces from patients with active alcohol abuse than controls. Total levels of LCFA correlated with those of lactobacilli in fecal samples from patients with active alcohol abuse but not in controls., Conclusions: In humans and mice, alcohol causes intestinal dysbiosis, reducing the capacity of the microbiome to synthesize saturated LCFA and the proportion of Lactobacillus species. Dietary approaches to restore levels of saturated fatty acids in the intestine might reduce ethanol-induced liver injury in patients with alcoholic liver disease., (Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
6. Cysteine-rich domains of muc3 intestinal mucin promote cell migration, inhibit apoptosis, and accelerate wound healing.
- Author
-
Ho SB, Dvorak LA, Moor RE, Jacobson AC, Frey MR, Corredor J, Polk DB, and Shekels LL
- Subjects
- Amino Acid Sequence, Animals, Cell Proliferation drug effects, Cells, Cultured, Cysteine, ErbB Receptors drug effects, Humans, Mice, Molecular Sequence Data, Mucin-3, Mucins chemistry, Protein Structure, Tertiary, Recombinant Proteins pharmacology, Apoptosis drug effects, Cell Movement drug effects, Epidermal Growth Factor pharmacology, Mucins pharmacology, Wound Healing drug effects
- Abstract
Background & Aims: Muc3 intestinal mucin contains an extracellular cysteine-rich domain with 2 epidermal growth factor (EGF)-like motifs. The aim of this study was to determine the functional properties of Muc3 proteins., Methods: Glutathione S-transferase-fusion proteins containing both Muc3 EGF-like domains (m3EGF1,2) or truncated versions (m3EGF1 and m3EGF2) were purified from Escherichia coli. Mouse colon (young adult mouse colon) and human A431 and LoVo cells were examined for migration and tyrosine phosphorylation in response to recombinant proteins. LoVo cells were transfected with a human MUC3A transmembrane-EGF1,2 construct and a stable clone was isolated (LhM3c14). Endogenous MUC3A in LoVo was inhibited by specific small interfering RNA transfection. Apoptosis was quantitated by nuclear morphology or terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick-end labeling assay. Colitis was induced in mice by oral 5% dextran sodium sulfate or rectal 5% acetic acid, followed by enema treatments., Results: m3EGF1,2 stimulated cell migration in all cell lines, but did not induce proliferation. Migration was inhibited by a tyrosine phosphorylation inhibitor, genistein, but not by the EGF receptor inhibitor, tyrphostin (AG1478). Inhibition of endogenous MUC3A in LoVo reduced baseline migration. Tyrosine phosphorylation of ErbB receptors was not observed after treatment of cells with m3EGF1,2. LoVo cells pretreated with m3EGF1,2 and transfected LhM3c14 cells showed reduced apoptosis in response to tumor necrosis factor alpha or Fas-receptor stimulation. Administration of m3EGF1,2 per rectum significantly reduced mucosal ulceration and apoptosis in experimental acute colitis. Truncated proteins m3EGF1 and m3EGF2 had no effect., Conclusions: The Muc3 mucin cysteine-rich domain plays an active role in epithelial restitution, and represents a potential novel therapeutic agent for intestinal wound healing.
- Published
- 2006
- Full Text
- View/download PDF
7. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study.
- Author
-
Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, and Wright T
- Subjects
- Aged, Antiviral Agents therapeutic use, Case-Control Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Hepatitis C, Chronic diagnosis, Humans, Interferon alpha-2, Liver Function Tests, Male, Middle Aged, Patient Selection, Probability, Prospective Studies, Recombinant Proteins, Reference Values, Risk Assessment, Severity of Illness Index, Statistics, Nonparametric, Survival Rate, Treatment Outcome, Alcohol Drinking adverse effects, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic mortality, Interferon-alpha therapeutic use, Ribavirin therapeutic use
- Abstract
Background & Aims: Patients with hepatitis C virus (HCV) infection who use alcohol have been excluded from clinical trials; therefore, outcomes with antiviral therapy are unknown. The aim of the study was to determine the impact of alcohol use on HCV treatment outcomes., Methods: Subjects using alcohol were categorized as follows: no alcohol versus regular alcohol use, quantity consumed (none, <6 drinks/day, >/=6 drinks/day), CAGE score <2 or >/=2, and recent alcohol use (past 12 months). Patients were treated with interferon plus ribavirin., Results: A total of 4061 subjects were enrolled, and 726 (18%) received treatment. Alcohol use (past and within 12 months) reduced treatment candidacy. Past alcohol use did not affect the end-of-treatment response, sustained virologic response (SVR), and treatment discontinuation rates. However, recent alcohol use resulted in higher treatment discontinuation (40% vs 26%; P = .0002) and tended to reduce the SVR (14% vs 20%; P = .06), but when patients who discontinued treatment were excluded from analysis, the trend in favor of nondrinkers for SVR disappeared (25% vs 23%). These findings were also consistent in subgroup analyses on race and genotype., Conclusions: Eligibility for anti-HCV treatment was reduced in past and recent drinkers. Recent alcohol use was associated with increased treatment discontinuation and lower SVR. However, patients who use alcohol and completed the treatment had a response comparable to that of nondrinkers. Patients with a history of alcohol use should not be excluded from HCV therapy. Instead, additional support should be provided to these patients to ensure their ability to complete treatment.
- Published
- 2006
- Full Text
- View/download PDF
8. Molecular staging of colorectal cancer: a step forward
- Author
-
Bresalier RS and Ho SB
- Published
- 1999
- Full Text
- View/download PDF
9. Expression cloning of gastric mucin complementary DNA and localization of mucin gene expression.
- Author
-
Ho SB, Roberton AM, Shekels LL, Lyftogt CT, Niehans GA, and Toribara NW
- Subjects
- Amino Acid Sequence, Base Sequence, Blotting, Western, Cloning, Molecular, Enzyme-Linked Immunosorbent Assay, Epithelium metabolism, Genomic Library, Humans, Immunohistochemistry, Molecular Sequence Data, Mucin 5AC, Mucin-5B, Mucins chemistry, Mucins metabolism, RNA, Messenger metabolism, Repetitive Sequences, Nucleic Acid, DNA, Complementary genetics, Gastric Mucosa metabolism, Gene Expression, Mucins genetics
- Abstract
Background & Aims: Secretory mucins play an important role in gastric cytoprotection and are derived from a heterogeneous family of genes. The aim of this study was to determine the specific type and location of mucin gene expression in the human stomach., Methods: Expression cloning was performed by screening a human gastric complementary DNA expression library with antisera against deglycosylated gastric mucin. RNA analysis and immunohistochemistry were used to quantify and localize mucin gene expression., Results: Sequencing of positive clones revealed two clones containing tandem repeats. The first contained a 169-amino acid repeat and was named MUC6 (as previously described). The second contained the same 8-amino acid repeat consensus sequence (APTTSTTS) as complementary DNAs previously isolated from a tracheobronchial complementary DNA library and was labeled MUC5 (or MUC5AC). RNA analysis indicated that the gastric epithelium contains high levels of MUC5 and MUC6 messenger RNA with little or no MUC2, MUC3, and MUC4 messenger RNA. Immunohistochemical analysis showed that surface mucous cells of the cardia, fundus, and antrum expressed MUC5 peptide. In contrast, MUC6 peptide expression was limited to mucous neck cells of the fundus, antral-type glands of the antrum and cardia, and Brunner's glands of the duodenum., Conclusions: MUC5 and MUC6 represent major secretory mucins in the stomach and are localized to distinct cell types.
- Published
- 1995
- Full Text
- View/download PDF
10. Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer.
- Author
-
Chang SK, Dohrman AF, Basbaum CB, Ho SB, Tsuda T, Toribara NW, Gum JR, and Kim YS
- Subjects
- Colon chemistry, Colon cytology, Colonic Neoplasms pathology, DNA analysis, DNA genetics, DNA, Neoplasm analysis, DNA, Neoplasm genetics, Humans, Immunohistochemistry, In Situ Hybridization, Intestine, Small cytology, Mucins physiology, Peptides physiology, RNA, Messenger genetics, Colonic Neoplasms chemistry, Gastric Mucins, Intestine, Small chemistry, Mucins analysis, Mucins genetics, Peptides analysis, Peptides genetics, RNA, Messenger analysis
- Abstract
Background/aims: Several studies have reported Northern blot data showing that mucin is expressed in a tissue-specific manner. To determine whether expression is limited to specific cell types within these tissues requires histological analysis., Methods: Both immunocytochemistry and in situ hybridization were used to identify cell types expressing the MUC2 and MUC3 mucins in the human small intestine, colon, and colon carcinoma., Results: In the normal small intestine and colon, an antibody recognizing the MUC2 apomucin stained goblet cells. In contrast, an antibody recognizing the MUC3 apomucin stained both goblet and absorptive cells. Consistent with this, in situ hybridization showed MUC2 messenger RNA (mRNA) only in goblet cells and MUC3 mRNA in both goblet and absorptive cells. In several samples of moderately well-differentiated colon cancer, MUC2 and MUC3 showed distinct patterns of expression, but the expression level of each was reduced compared with levels in normal tissue; there was considerable tumor-to-tumor and cell-to-cell variability using both mucin antibodies and complementary DNA probes., Conclusions: Individual mucin genes have distinct patterns of expression within mucin-producing tissues, suggesting that the various mucin gene products play distinct functional roles.
- Published
- 1994
- Full Text
- View/download PDF
11. Cell lineage markers in premalignant and malignant colonic mucosa.
- Author
-
Ho SB, Itzkowitz SH, Friera AM, Jiang SH, and Kim YS
- Subjects
- Carcinoembryonic Antigen analysis, Cell Transformation, Neoplastic, Chromogranin A, Chromogranins analysis, Humans, Immunoenzyme Techniques, Mucins analysis, Muramidase analysis, Secretory Component analysis, Stem Cells pathology, Biomarkers, Tumor analysis, Colon pathology, Colonic Polyps pathology, Colorectal Neoplasms pathology, Intestinal Mucosa pathology
- Abstract
Normal colonic epithelial cells consist of several cell types or lineages that are thought to arise from a common stem cell precursor. Neoplastic transformation may occur at different stages in the differentiation of a colonic stem cell to produce tumors that may retain characteristic cell lineage phenotypes. In this study, immunohistochemical techniques were used to identify cell lineage-related markers in fetal, normal, hyperplastic, adenomatous, and cancerous colonic tissue. These markers consisted of secretory component (columnar cells), a purified mucin antigen (mucous or goblet cells), chromogranin A (enteroendocrine cells), lysozyme (Paneth cells), and carcinoembryonic antigen (panepithelial cell marker). Colonic neoplasms, like normal mucosa, predominantly expressed the markers of columnar and goblet cell lineages. Chromogranin A was expressed in a small population of cells in most normal and fetal colonic crypts. Chromogranin A reactive cells were found in 55% of hyperplastic polyps, 31% of adenomatous polyps, and 33% of carcinomas. Lysozyme reactivity was rare in fetal, normal, and hyperplastic specimens, but was present in 86% of adenomas and 40% of carcinomas. Of 42 primary carcinomas, 9% were "pluripotent" and expressed markers of all four cell lineages. In addition to columnar and goblet cell markers, 7% expressed both enteroendocrine and Paneth cell markers, 17% expressed enteroendocrine cell markers, and 24% expressed Paneth cell markers. Two cases (5%) lacked expression of any of the cell lineage markers. The remainder expressed only columnar and goblet cell markers. The markers used in this study appear to identify the major cell lineages of fetal and normal colonic epithelium and can be used to delineate the altered cell lineage phenotypes in premalignant and malignant colonic mucosa.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.